Compile Data Set for Download or QSAR
maximum 50k data
Found 5 Enz. Inhib. hit(s) with Target = 'Prolyl hydroxylase EGLN3' and Ligand = 'BDBM107704'
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMT: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProlyl hydroxylase EGLN3(Homo sapiens (Human))
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US11426393, Compound Table XV.11 | US8598210, 119 ...)
Affinity DataIC50:  390nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails US Patent